comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 11:57:44 - browse：7

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： VC firm RA Capital starts a new synthetic biology incubator

WSS

An outrageous hospital charge: I paid $710 for an hour of babysitting

Microbiome research is starting to find links to chronic diseases

Experts study whether long Covid risk adds up with each reinfection

EpiPen alternative approval delay highlights citizen petition issue

Senate HELP committee spars over health care workforce policies

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Interest rates are at a 22

Medical leaders decry Supreme Court decision on affirmative action

As the dark side of IVF slowly comes into focus, even more transparency is needed

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

It's been 20 years since Dolly the sheep. Where's my clone?

Heart attack and stroke risk calculators need revising

Changes to biosimilar regulatory framework must prioritize patients

23andMe had bad news about my health. I wish a person had delivered it

What Congress can do to address the rural doctor shortage

Wikipedia

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

STAT Virtual Event: Putting AI to the Test

Experts study whether long Covid risk adds up with each reinfection

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

Ending health disparities requires full federal government, panel says

Ukraine and a new approach to mental health in war

focus

focus

leisure time

Wikipedia